15 minute intraday candlestick chart, ~15 minute delayCurrently unavailable for this symbol.
Try again later today or try daily, weekly, monthly or quarterly charts.
15 minute intraday candlestick chart, ~15 minute delayCurrently unavailable for this symbol.
Try again later today or try daily, weekly, monthly or quarterly charts.
LLY News
11-Feb-2025 1:28 PM CST - Insider Monkey Eli Lilly and Company (LLY): A Bull Case Theory We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will summarize the bulls' thesis on LLY.
7-Feb-2025 2:43 PM CST - Investing Eli Lilly's rating gets an upgrade to Aa3 by Moody's Ratings Ratings has upgraded the issuer rating and senior unsecured notes ratings of global pharmaceutical company Eli Lilly and Company (NYSE:LLY) to Aa3 from A1. The Prime-1 short-term rating was affirmed.
6-Feb-2025 1:18 PM CST - MSN What Are Wall Street Analysts' Target Price for Eli Lilly Stock? With a market cap of $799.5 billion, Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a leading global pharmaceutical firm renowned for its innovative contributions to healthcare. The company has developed notable medications such as Prozac for depression,
6-Feb-2025 9:47 AM CST - Zacks LLY's Q4 Earnings Beat, Mounjaro, Zepbound Sales Fall Shy of Estimates Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share ("EPS") of $5.32, which beat the Zacks Consensus Estimate of $5.03 per share. Earnings rose 114% year over year. Adjusted earnings included an acquired in-process research and development (IPR&D) charge of 19 cents per share.
5-Feb-2025 2:07 PM CST - Investing Truist maintains Eli Lilly stock Buy rating, $1038 target Truist Securities reaffirmed its Buy rating and $1,038.00 price target for Eli Lilly and Company (NYSE:LLY) shares, with analyst targets ranging from $580 to $1,190. The company, which has demonstrated strong revenue growth of 27.
3-Feb-2025 9:41 AM CST - Investing Eli Lilly stock price target raised to $1,038 by Truist Securities Truist Securities updated their financial model for Eli Lilly and Company (NYSE:LLY), leading to an increased price target on the pharmaceutical giant's shares. The new price target is set at $1,038.00,
3-Feb-2025 7:19 AM CST - Zacks Eli Lilly Stock Before Q4 Earnings: To Buy or Not to Buy? Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.72 billion and $5.
3-Feb-2025 7:10 AM CST - Insider Monkey Why Eli Lilly and Company (LLY) Is the Best Cancer Stock to Buy According to Hedge Funds Eli Lilly & Co. (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. Its products span oncology, diabetes, immunology, neuroscience, and other therapies. The company is one of the best stocks to buy in the pharmaceutical industry, and management expects a 32% revenue growth in fiscal 2025.
Latest LLY Trades by Congress Members
21-JAN-2025 - Marjorie Taylor Greene, GA (District 14) purchased between $1,001 and $15,000.
11-Feb-2025 1:28 PM CST - Insider Monkey Eli Lilly and Company (LLY): A Bull Case Theory We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will summarize the bulls' thesis on LLY.
7-Feb-2025 2:43 PM CST - Investing Eli Lilly's rating gets an upgrade to Aa3 by Moody's Ratings Ratings has upgraded the issuer rating and senior unsecured notes ratings of global pharmaceutical company Eli Lilly and Company (NYSE:LLY) to Aa3 from A1. The Prime-1 short-term rating was affirmed.
6-Feb-2025 1:18 PM CST - MSN What Are Wall Street Analysts' Target Price for Eli Lilly Stock? With a market cap of $799.5 billion, Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a leading global pharmaceutical firm renowned for its innovative contributions to healthcare. The company has developed notable medications such as Prozac for depression,
6-Feb-2025 9:47 AM CST - Zacks LLY's Q4 Earnings Beat, Mounjaro, Zepbound Sales Fall Shy of Estimates Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share ("EPS") of $5.32, which beat the Zacks Consensus Estimate of $5.03 per share. Earnings rose 114% year over year. Adjusted earnings included an acquired in-process research and development (IPR&D) charge of 19 cents per share.
5-Feb-2025 2:07 PM CST - Investing Truist maintains Eli Lilly stock Buy rating, $1038 target Truist Securities reaffirmed its Buy rating and $1,038.00 price target for Eli Lilly and Company (NYSE:LLY) shares, with analyst targets ranging from $580 to $1,190. The company, which has demonstrated strong revenue growth of 27.
3-Feb-2025 9:41 AM CST - Investing Eli Lilly stock price target raised to $1,038 by Truist Securities Truist Securities updated their financial model for Eli Lilly and Company (NYSE:LLY), leading to an increased price target on the pharmaceutical giant's shares. The new price target is set at $1,038.00,
3-Feb-2025 7:19 AM CST - Zacks Eli Lilly Stock Before Q4 Earnings: To Buy or Not to Buy? Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.72 billion and $5.
3-Feb-2025 7:10 AM CST - Insider Monkey Why Eli Lilly and Company (LLY) Is the Best Cancer Stock to Buy According to Hedge Funds Eli Lilly & Co. (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. Its products span oncology, diabetes, immunology, neuroscience, and other therapies. The company is one of the best stocks to buy in the pharmaceutical industry, and management expects a 32% revenue growth in fiscal 2025.